EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

KMT2D depletion promotes KRAS-induced pancreatic carcinogenesis independent of TP53

Ezequiel J Tolosa, Glancis L Raja Arul, Ashley N Sigafoos, Victoria Ferrero, David R Pease, Luciana L Almada, Renzo E Vera, Nicole M Pena Ruiz, Tara L Hogenson, Kayla C LaRue-Nolan, Brooke R Tader, Rondell P Graham und 6 weitere

Journal of Biological Chemistry · 2026-07 · 302 (7) · 113203

DOI: 10.1016/j.jbc.2026.113203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026-07. Verfasst von Ezequiel J Tolosa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Pancreatic Neoplasms, Tumor Suppressor Protein p53, DNA-Binding Proteins. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Pancreatic NeoplasmsTumor Suppressor Protein p53DNA-Binding ProteinsCarcinoma, Pancreatic DuctalNeoplasm ProteinsCarcinogenesisAnimalsHumansMice

Stichwörter der Autor:innen

KMT2DKRASgene expressionpancreatic cancertumor suppression

Substanzen

Proto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53DNA-Binding ProteinsKMT2D protein, humanNeoplasm ProteinsKRAS protein, human

Autor:innen und Institutionen

  • Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA; Molecular Pharmacology and Experimental Therapeutics Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, M…
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Endocrinology, Metabolism, Diabetes, and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: FernandezZapico.Martin@mayo.edu.

Förderung

  • NCI NIH HHS
  • NIH National Cancer Institute

Zitieren

APA

Tolosa, E. J., Raja Arul, G. L., Sigafoos, A. N., Ferrero, V., Pease, D. R., Almada, L. L., Vera, R. E., Pena Ruiz, N. M., Hogenson, T. L., LaRue-Nolan, K. C., Tader, B. R., Graham, R. P., Brown, M., Hagen, C. E., Matveyenko, A. V., Carr, R. M., Ge, K., & Fernandez-Zapico, M. E. (2026). KMT2D depletion promotes KRAS-induced pancreatic carcinogenesis independent of TP53. Journal of Biological Chemistry, 302(7), 113203. https://doi.org/10.1016/j.jbc.2026.113203

Vancouver

Tolosa EJ, Raja Arul GL, Sigafoos AN, Ferrero V, Pease DR, Almada LL, et al. KMT2D depletion promotes KRAS-induced pancreatic carcinogenesis independent of TP53. Journal of Biological Chemistry. 2026;302(7):113203. doi:10.1016/j.jbc.2026.113203

BibTeX
@article{Tolosa2026,
  author = {Tolosa, Ezequiel J and Raja Arul, Glancis L and Sigafoos, Ashley N and Ferrero, Victoria and Pease, David R and Almada, Luciana L and Vera, Renzo E and Pena Ruiz, Nicole M and Hogenson, Tara L and LaRue-Nolan, Kayla C and Tader, Brooke R and Graham, Rondell P and Brown, Mathew and Hagen, Catherine E and Matveyenko, Aleksey V and Carr, Ryan M and Ge, Kai and Fernandez-Zapico, Martin E},
  title = {KMT2D depletion promotes KRAS-induced pancreatic carcinogenesis independent of TP53},
  journal = {Journal of Biological Chemistry},
  year = {2026},
  volume = {302},
  number = {7},
  pages = {113203},
  doi = {10.1016/j.jbc.2026.113203}
}
Kostenlos starten →